Table 2 Antiviral activity (IC50) and cytotoxicity (CC50) of NYAD-201, NYAD-202 and NYAD-203 in laboratory-adapted and primary HIV-1 isolates
From: Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain
HIV-1 virus | Subtype | Cell Type | Coreceptor | IC50 (μM±SD) | |||
|---|---|---|---|---|---|---|---|
NYAD-201 | NYAD-202 | NYAD-203 | |||||
Laboratory Strains | IIIB | B | MT-2 | X4 | 4.29 ± 0.62 | 2.36 ± 0.33 | 6.29 ± 0.54 |
MN | B | MT-2 | X4 | 3.03 ± 0.61 | 2.47 ± 0.71 | ||
SF2 | B | MT-2 | R5X4 | 5.06 ± 1.37 | 4.48 ± 0.84 | ||
RF | B | MT-2 | X4 | 2.84 ± 0.63 | 2.64 ± 0.39 | ||
BaL | B | PBMC | R5 | 4.73 ± 1.92 | 2.23 ± 0.44 | ||
89.6 | B | PBMC | R5X4 | 5.21 ± 0.87 | 3.47 ± 0.22 | ||
RT-Resistant Isolate | AZT-R | B | MT-2 | X4 | 8.0 ± 1.27 | 4.53 ± 1.19 | 11.1 ± 3.82 |
PR-Resistant Isolate | HIV-1 RF/L-323-12-3 | B | MT-2 | X4 | 5.6 ± 0.5 | 3.5 ± 0.6 | |
Primary isolates | 93RW024 | A | PBMC | R5X4 | 9.88 ± 0.3 | 3.71 ± 0.19 | |
92UG029 | A | PBMC | X4 | 7.88 ± 1.01 | 3.97 ± 0.47 | ||
92US657 | B | PBMC | R5 | 6.72 ± 0.98 | 3.61 ± 0.57 | ||
93IN101 | C | PBMC | R5 | 1.58 ± 0.57 | 5.53 ± 0.39 | ||
98CN009 | C | PBMC | R5 | 5.31 ± 0.83 | 4.08 ± 0.92 | ||
CMU02 | EA | PBMC | X4 | 7.36 ± 0.69 | 4.2 ± 0.01 | ||
93BR020 | F | PBMC | R5X4 | 2.78 ± 0.57 | 2.51 ± 0.43 | ||
RU570 | G | PBMC | R5 | 7.48 ± 1.21 | 6.34 ± 2.22 | ||
BCF02 | (Group 0) | PBMC | R5 | 15.84 ± 3.43 | 6.2 ± 1.2 | ||
Peptides | CC 50 (μM) in MT-2 | CC 50 (μM)in PBMC | |||||
NYAD-201 | >115 | >115 | |||||
NYAD-202 | 30.2 ± 4.32 | >116 | |||||
NYAD-203 | 13.24 ± 0.5 | 15.96 ± 1.47 | |||||